Physician profile
Taha Rasul
NPI 1376233429
$1,481.29
in general payments reported to CMS, 2019-2025
14 companies · $737 in 2025
The $737 reported for 2025 was more than what 84% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $744 · 2025: $737.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,481.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,481.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $271.01 | 2024-2025 | |
| Ucb, INC. | $218.79 | 2024-2025 | Bimzelx |
| Organon LLC | $138.73 | 2025 | Vtama |
| Glaxosmithkline, LLC. | $122.55 | 2024 | Jemperli |
| Astrazeneca Pharmaceuticals Lp | $121.75 | 2024 | Andexxa |
| Regeneron Healthcare Solutions, INC. | $118.74 | 2024 | Libtayo |
| Convatec INC. | $105.56 | 2025 | |
| Galderma Laboratories, L.P. | $100.00 | 2025 | Nemluvio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $89.08 | 2024 | Spevigo |
| Novartis Pharmaceuticals Corporation | $72.84 | 2024 | |
| Almirall LLC | $48.34 | 2025 | Klisyri |
| Sun Pharmaceutical Industries INC. | $28.23 | 2024 | |
| Verrica Pharmaceuticals INC. | $24.87 | 2024 | Ycanth |
| Lilly USA, LLC | $20.80 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taha Rasul listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.